Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 1/20 | 0.35 |
| ▸ | CTSL | P07711 | 4/20 | 0.34 |
| ▸ | CTSK | P43235 | 4/20 | 0.34 |
| ▸ | CTSS | P25774 | 3/20 | 0.34 |
| ▸ | PARP1 | P09874 | 1/20 | 0.34 |
| ▸ | HSD11B1 | P28845 | 2/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.33 |
| ▸ | F2 | P00734 | 1/20 | 0.33 |
| ▸ | F10 | P00742 | 1/20 | 0.33 |
| ▸ | PRSS1 | P07477 | 1/20 | 0.33 |
| ▸ | DPP4 | P27487 | 1/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.32 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.32 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4045821 | 0.90 | PARP1 (0.35) | TSHRCTSLCTSKCTSSPARP1 | |
| SCHEMBL4047202 | 0.85 | CTSK (0.44) | CTSLCTSKCTSS | |
| SCHEMBL4046440 | 0.83 | FKBP1A (0.40) | — | |
| SCHEMBL4041605 | 0.81 | MAPK14 (0.40) | TSHRCTSLCTSKCTSSALDH1A1 | |
| SCHEMBL4041121 | 0.80 | ALDH1A1 (0.40) | TSHRCTSLCTSKCTSSALDH1A1 | |
| SCHEMBL4042575 | 0.80 | DPP4 (0.41) | TSHRCTSLCTSKCTSSPARP1 | |
| SCHEMBL6208713 | 0.80 | PARP1 (0.36) | TSHRPARP1ALDH1A1F2F10 | |
| SCHEMBL4042325 | 0.79 | DPP4 (0.40) | TSHRCTSLCTSKCTSSPARP1 | |
| SCHEMBL4044728 | 0.79 | DPP4 (0.40) | CTSLCTSKCTSSPARP1DPP4 | |
| SCHEMBL4046221 | 0.78 | DPP4 (0.40) | CTSKPARP1ALDH1A1F2DPP4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1546150-B1 | PYRROLE DERIVATIVES AS INHIBITORS OF CYTEINE PROTEASES | AMURA THERAPEUTICS LTD (GB) | 2009-03-04 | — | — | EP | claimed |
| US-20060100431-A1 | Biologically active compounds | AMURA THERAPEUTICS LIMITED (GB) | 2006-05-11 | — | — | US | claimed |
| EP-1546150-B1 | PYRROLE DERIVATIVES AS INHIBITORS OF CYTEINE PROTEASES | AMURA THERAPEUTICS LTD (GB) | 2009-03-04 | — | — | EP | disclosed |
| US-20060100431-A1 | Biologically active compounds | AMURA THERAPEUTICS LIMITED (GB) | 2006-05-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060100431-A1 | Biologically active compounds | SOST, CTSK, CTSS | TSHR 1023/4885CTSL 57/4885CTSK 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.